3-醛基-1H-吲哚-4-甲酸甲酯 | 53462-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 3-醛基-1H-吲哚-4-甲酸甲酯
• 中文别名: 4-甲酸甲酯吲哚-3-甲醛；吲哚-4-甲酸甲酯-3-甲醛；3-甲酰吲哚-4-羧酸甲酯
• 英文名称: methyl 3-formylindole-4-carboxylate
• 英文别名: 3-Formyl-indol-4-carbonsaeure-methylester；3-Formylindole-4-carboxylic acid methyl ester；methyl 3-formyl-1H-indole-4-carboxylate
• CAS: 53462-88-7
• 化学式: C₁₁H₉NO₃
• mdl: MFCD06656838
• 分子量: 203.197
• InChiKey: HWQJAOMFBDZMPB-UHFFFAOYSA-N

物化性质

• 熔点：
  134-135 °C(Solv: benzene (71-43-2))
• 沸点：
  404.4±25.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：2-8°C，避光保存，惰性气氛环境。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-formylindole-4-carboxylate
Synonyms: Methyl 3-formyl-1H-indole-4-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-formylindole-4-carboxylate
CAS number: 53462-88-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H9NO3
Molecular weight: 203.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-醛基-1H-吲哚-4-甲酸甲酯 在 乙酸铵 作用下， 以 硝基甲烷 、 水 、 乙酸乙酯 为溶剂， 生成 4-methoxycarbonyl-3-(2-nitrovinyl)indole
  参考文献：
  名称：

  6-oxoazepinoindole compounds, and pharmaceutical compositions containing

  摘要：

  一般式I对应的药理活性化合物如下：##STR1## 其中，R.sup.1代表氢、较低的烷基或环烷基-烷基基团或可选择性取代的苯基-较低的烷基基团，R.sup.2代表氢或可选择性取代于氮原子的α-位置的较低烷氧基的较低烷基基团，R.sup.3代表氢、较低的烷基、较低烷氧基、卤素或羟基，n代表1或，如果-(CH.sub.2).sub.n-链在环结构的4位，则也代表2，R.sup.4代表氢、较低的烷基、环烷基、环烷基-较低的烷基或可选择性取代的苯基-较低的烷基基团，R.sup.5代表氢、较低的烷基、环烷基、环烷基-较低的烷基或可选择性取代的苯基-较低的烷基基团，或R.sup.4和R.sup.5与它们连接的氮原子一起形成杂环，D代表键，或者如果R.sup.4和R.sup.5不代表氢，则还代表-N.dbd.CH-基团。此外，还描述了它们的生理上可接受的酸加成盐，以及制备它们的过程和中间体。

  公开号：

  US05272143A1
• 作为产物：
  描述：

  吲哚-4-羧酸甲酯 在 sodium hydroxide 、 三氯氧磷 作用下， 以 N-甲基乙酰胺 、 乙醚 、 二氯甲烷 、 水 为溶剂， 生成 3-醛基-1H-吲哚-4-甲酸甲酯
  参考文献：
  名称：

  6-oxoazepinoindole compounds, and pharmaceutical compositions containing

  摘要：

  一般式I对应的药理活性化合物如下：##STR1## 其中，R.sup.1代表氢、较低的烷基或环烷基-烷基基团或可选择性取代的苯基-较低的烷基基团，R.sup.2代表氢或可选择性取代于氮原子的α-位置的较低烷氧基的较低烷基基团，R.sup.3代表氢、较低的烷基、较低烷氧基、卤素或羟基，n代表1或，如果-(CH.sub.2).sub.n-链在环结构的4位，则也代表2，R.sup.4代表氢、较低的烷基、环烷基、环烷基-较低的烷基或可选择性取代的苯基-较低的烷基基团，R.sup.5代表氢、较低的烷基、环烷基、环烷基-较低的烷基或可选择性取代的苯基-较低的烷基基团，或R.sup.4和R.sup.5与它们连接的氮原子一起形成杂环，D代表键，或者如果R.sup.4和R.sup.5不代表氢，则还代表-N.dbd.CH-基团。此外，还描述了它们的生理上可接受的酸加成盐，以及制备它们的过程和中间体。

  公开号：

  US05272143A1

文献信息

• Pyrroloisoquinoline derivatives
  申请人：Ayerst, McKenna and Harrison Ltd.

  公开号：US03950343A1

  公开（公告）日：1976-04-13

  1,3,4,5-Tetrahydropyrrolo[4,3,2-de]isoquinoline and its N-alkyl derivatives are disclosed. The compounds are antidepressant and antihypertensive agents. Methods for their preparation and use are disclosed.

  1,3,4,5-四氢吡咯并[4,3,2-de]异喹啉及其N-烷基衍生物已被披露。这些化合物是抗抑郁和降压药物。其制备和使用方法也已被披露。
• [EN] EP1 RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR EP1
  申请人：ESTEVE LABOR DR

  公开号：WO2013037960A1

  公开（公告）日：2013-03-21

  The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

  本发明属于EP1受体配体领域。更具体地，它涉及具有对EP1受体具有很高亲和力和选择性的一般式(I)化合物。该发明还涉及它们的制备方法，以及它们作为治疗和/或预防由EP1受体介导的疾病或紊乱的药物的用途，以及包含它们的药物组合物。
• Benzamide derivatives having a vasopressin antagonistic activity
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06207693B1

  公开（公告）日：2001-03-27

  This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by general formula (I): wherein R1 is aryl optionally substituted with lower alkoxy, etc., R2 is lower alkyl, etc., R3 is hydrogen, etc., A is NH, etc., E is etc., X is —CH═CH—, —CH═N—, or S, and Y is a condensed heterocyclic group, etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof and to a pharmaceutical composition comprising the same.

  这项发明涉及新的苯甲酰胺衍生物，它们具有抗血管加压素活性，并由通式（I）表示： 其中R1是可选地被低级烷氧基取代的芳基等， R2是低级烷基等， R3是氢等， A是NH等， E是 等， X是—CH═CH—，—CH═N—或S，而 Y是稠合杂环基等， 以及它们的药用可接受盐，其制备过程以及包含它们的药物组合物。
• Phenotype-based discovery of a HeLa-specific cytotoxic molecule that downregulates HPV-mediated signaling pathways<i>via</i>oxidative damage
  作者：Sanghee Lee、Wansang Cho、Sungyoul Hong、Sihyeong Yi、Heejun Kim、Soo Yeon Baek、Hankum Park、Jinjoo Jung、Young Kee Shin、Seung Bum Park

  DOI：10.1039/c9ob01341e

  日期：——

  Selective bioactive compounds have emerged as major players in chemical biology for their potential in disrupting diverse biological pathways with minimal adverse effects.

  选择性生物活性化合物已经成为化学生物学领域的主要参与者，因为它们有可能以最小的副作用干扰多种生物途径。
• [EN] DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES DE DIAZEPINOINDOLE EN TANT QU'INHIBITEURS DE KINASE
  申请人：PFIZER

  公开号：WO2004063198A1

  公开（公告）日：2004-07-29

  Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions, such as cancers.

  蛋白激酶，如CHK-1，抑制以下式的三环化合物（其中R2、R3和R4如规范中定义）的药物组合物，含有所述化合物或其盐的有效量，可用作单一药剂或与抗肿瘤药剂或具有抗肿瘤效果的治疗放射剂结合，用于治疗疾病或病况，如癌症。